Báez-Gutiérrez, NereaRodríguez-Ramallo, HéctorPérez Moreno, María AntoniaRodriguez Arboli, EduardoAbdel-Kader Martín, Laila2022-12-052022-12-052021-08-28Báez-Gutiérrez N, Rodríguez-Ramallo H, Moreno MA, Arboli ER, Abdel-Kader Martín L. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia. Ther Adv Hematol. 2021 Aug 28;12:204062072110403352040-6207http://hdl.handle.net/10668/4453In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination treatment has an accelerated approval by the Food and Drug Administration for newly diagnosed AML adults who are 75 years of age or older or who have comorbidities and are not eligible to receive intensive induction chemotherapy. AML is the most common form of acute leukaemia in adults, with a median age at diagnosis of 68 years. Consequently, most of the patients included in the studies are elderly. Traditionally, young patients achieve higher remission rates compared with the elderly AML population. Although venetoclax combination therapy could become a treatment option for treating young patients with relapsed/refractory AML, this regimen has not been systematically tested in this setting. In this study, we summarize the currently available evidence on the treatment of venetoclax in combination with hypomethylating agents for the treatment of young relapsed/refractory AML patients, in addition to our experience in clinical practice with two case reports. Venetoclax, combined with hypomethylating agents, seems to be an effective option for young relapsed/refractory AML patients. However, due to the poor quality of the evidence, additional well-designed studies with greater numbers of patients are needed to confirm the effectiveness and safety of venetoclax combination regimens for this population.enAtribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/Acute myeloid leukaemiaHypomethylating agentRefractoryRelapsedVenetoclaxYoung patientsInduction chemotherapyLeucemia mieloide agudaPacientesQuimioterapia de inducciónTerapia combinadaTerapéuticaMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Persons::Persons::Age Groups::Adult::AgedMedical Subject Headings::Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Government::Federal Government::United States Government Agencies::United States Dept. of Health and Human Services::United States Public Health Service::United States Food and Drug AdministrationMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Induction ChemotherapyMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, AcuteMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Apoptosis Regulatory Proteins::Proto-Oncogene Proteins c-bcl-2Medical Subject Headings::Geographical Locations::Geographic Locations::Americas::North America::United StatesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality TherapyMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeuticsresearch article34471510open access10.1177/204062072110403352040-6215PMC8404627